AMLX

Amylyx Pharmaceuticals, Inc.
28.07 -0.81% 2026-10-28

Last 90d 2 insider sales

52-week range
10.83 41.14
1-month-4.1%
3-month+35.3%
1-year+97.3%
3-year+70.6%
vs 50-day-10.3%
vs 200-day+40.9%
Volatility87%
Beta0.92
$ vol/day$37M
ATH41.93
From ATH-33.1%
Next report2026-11-05
Nothing written about AMLX yet. Be the first — call it long or short with an entry we price for you, or post a neutral write-up that takes no side. Create a free account
2026AprJulOct

bought sold · bigger dot, bigger trade · follows the chart’s range

WhenPeople SizeValuePrice
22d sched 1 $830,904 27.84
1mo sell 5 $2,944,962 32.77
4mo sched 1 $538,868 17.25
5mo buy 1 $51,338 13.70
8mo sell 5 $1,156,129 14.59
8mo sell 1 $48,345 14.63
9mo sell 4 $557,858 14.16
9mo sell 2 $3,755,375 15.35
10mo sell 3 $208,071 11.82
10mo buy 1 $100,845 12.48
11mo sell 1 $94,423 13.98
1.1y sell 5 $1,319,156 13.45
1.2y sched 1 $246,150 8.30
1.6y sell 5 $261,838 3.53
1.6y buy 1 $37,000 3.70
1.7y sell 3 $34,067 3.20
1.7y sell 1 $13,132 3.21
1.7y sell 3 $95,096 3.76
1.8y sell 2 $60,440 3.75
1.9y sell 1 $30,032 5.37
2.1y sell 4 $183,453 3.00
2.1y buy 1 $101,200 2.63
2.1y buy 1 $106,500 2.41
2.1y buy 1 $220,000 2.16
2.5y sched 1 $19,655 1.82
2.5y buy 1 $9,450 1.82
2.6y sell 4 $217,305 18.92
2.7y sell 1 $53,241 18.44
2.8y sell 4 $281,039 15.88
2.9y buy 1 $59,880 14.11
3.2y sched 1 $128,704 20.18
3.5y sched 1 $875,560 27.18
3.5y sched 1 $347,344 27.35
3.5y sched 1 $1,513,770 31.06
3.6y sell 1 $884,512 28.75
3.6y sell 1 $4,896,561 29.94
3.6y sell 2 $2,777,744 28.39
3.6y sell 1 $2,024,494 29.16
3.6y sell 5 $10,266,573 30.80
3.6y buy 1 $31,990 30.80
3.6y sell 1 $296,921 30.76
3.6y sell 1 $7,433,459 32.23
3.7y sell 1 $1,687,500 34.59
3.7y sell 2 $1,860,033 33.93
3.7y sell 1 $3,578,103 34.84
3.8y sell 5 $690,818 36.36
4.1y sell 1 $41,721,456 29.57
4.3y sell 1 $1,254,642 21.93
4.6y buy 1 $5,000,002 22.95
4.8y buy 1 $5,000,002 18.93
4.8y buy 1 $43,700,000 21.50
4.8y buy 4 $829,958 17.23
2026AprJulOct

bought sold · bigger dot, bigger trade · follows the chart’s range

CJChristopher L. Jacobs 1B 4.0y

1 member · 1 buys / 0 sells · $1K–$15K disclosed · latest filing Nov 16, 2022 · full tracker ›

WhenMemberSize AmountPrice then
4.0y buy CJ Christopher L. Jacobs $1K–$15K 33.61

Next report 2026-11-05 (Thursday, before open, in 7 days) · EPS estimate -0.37. It has finished the next session higher 42% of the time, average move 7.4%.

Day-after move, last 12 reports, oldest left.

ReportedEst.Actual SurpriseGapDay 1Day 5
2026-08-06 miss -0.36 -0.39 -9.0% -3.4% +10.7% +2.9%
2026-05-07 miss -0.34 -0.37 -8.7% -0.5% -5.4% -13.6%
2026-03-03 beat -0.34 -0.30 +12.2% +0.8% -7.8% -2.1%
2025-11-06 beat -0.43 -0.37 +13.9% -2.0% -5.9% -6.2%
2025-08-07 miss -0.45 -0.46 -1.2% -2.3% -4.3% +2.7%
2025-05-08 beat -0.50 -0.42 +16.0% +4.1% -6.0% -7.2%
2025-03-04 beat -0.59 -0.55 +6.8% -6.7% +0.3% +24.3%
2024-11-07 miss -0.91 -1.07 -16.9% -3.5% +5.1% -19.3%
2024-08-08 beat -0.82 -0.62 +23.9% +1.6% -4.3% +14.9%
2024-05-09 miss -0.01 -0.12 -1946.5% -4.7% -2.1% -5.2%
2024-02-22 miss 0.23 0.07 -69.3% +8.1% +21.1% +23.1%
2023-11-09 miss 0.44 0.30 -31.3% -29.7% -31.9% -32.6%
2023-08-10 beat 0.07 0.31 +342.9% -0.8% +2.0% -4.5%
2023-05-11 beat -0.25 0.02 +108.1% +5.8% -4.0% -7.4%
2023-03-13 beat -0.84 -0.65 +22.8% +19.3% +9.4% -2.9%
2022-11-10 beat -0.98 -0.92 +5.7% -0.9% -3.9% -1.1%
2022-08-11 miss -0.84 -0.93 -10.3% -0.7% -3.6% -4.4%
2022-05-12 miss -0.69 -0.93 -34.8% +0.7% +13.0% +16.3%
2022-03-31 miss -0.64 -4.15 -548.4% -6.5% +0.2% +6.2%
Model view — historical tendencies for the days ahead, not a forecast
Next 1 day
+0.4%
Next 1 week
+1.8%
Next 1 month
+2.4%
Seasonality
Not enough history
20-year seasonality chart →
Mean reversion
Neutral — RSI(2) at 58
RSI(2) under 15 is oversold (this name has historically bounced); over 85 is overbought. Its dip-buy edge in history is -0.48%/day.
Mean-reversion stats →
1-month breakdown — Market · β 0.92 +2.4% · Seasonal tilt (3y) +0.0%
$37M/day volume 87% volatility +97% 1-year -33% from ATH
52-week range · 57% of the way up · -32% from the high
$10.83$41.14

Not investment advice.